Best practice advice for diagnosing, managing NAFLD in lean individuals
Can bacteria in your gut boost cancer therapies? A San Diego startup thinks so
21 July 2022Pharmacist-based deprescribing successfully reduced older adults’ exposure to anticholinergic drugs
21 July 2022Best practice advice for diagnosing, managing NAFLD in lean individuals
Nonalcoholic fatty liver disease (NAFLD) is well recognized as a leading cause of chronic liver disease, affecting more than 25 percent of the U.S. and global population. One in four individuals with NAFLD have nonalcoholic steatohepatitis—a type of liver disease in which fat builds up in the liver of people who drink little or no alcohol, which is associated with significant morbidity and mortality due to complications of liver cirrhosis, hepatic decompensation (deterioration of liver function) and liver cancer.
